Brooklyn ImmunoTherapeutics (NYSE:BTX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Up 26.2 %

BTX opened at $0.40 on Friday. Brooklyn ImmunoTherapeutics has a 1-year low of $0.17 and a 1-year high of $10.10. The firm’s 50 day simple moving average is $0.86 and its two-hundred day simple moving average is $1.44. The company has a market capitalization of $23.52 million, a PE ratio of -0.18 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.